Key result
Bosentan effectively treats various forms of PAH including in children as monotherapy or combination therapy.
Bosentan is an effective treatment option for various forms of pulmonary arterial hypertension, including in pediatric populations.
Answers are grounded in this paper and cite their sources.
Supports bosentan in pediatric PAH; leaves open need for randomized trials to confirm efficacy.
At the present time evidential base on bosentan use comprises more randomized control trials results compared with other Lag-specific medications. Bosentan can be successfully used as monotherapy of in combination with medications of other groups in patients with idiopathic pulmonary hypertension (PH), pulmonary arterial hypertension (PAH) comorbid with connective tissue disease (PAH-CTD), HIV (PAH-HIV), congenital heart disorders (systemic-to-pulmonary shunts) - PAH-CHD, and also in PH treatment and for disease progression delay in patients with unimpaired functional class. It is the only Lag-specific medication approved for use in children and the only medication of this group included in the list of essential medicines. The articles presents literature review of clinical trials on bosentan and discusses indications, contradictions and side effects of its use.
No takes yet. Share an insight, caveat, or question.
Архипова et al. (2018) conducted a review in Pulmonary arterial hypertension. Bosentan was evaluated. Bosentan is an effective treatment for various forms of pulmonary arterial hypertension, including in children, and can be used as monotherapy or in combination with other medications.
Synapse has enriched 10 related papers. Consider them for comparative context: